Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Lack of historical evidence to support folic acid exacerbation of the neuropathy caused by vitamin B12 deficiency
Researchers developed it starting in the 1990s at Monash University with the specific goal of separating hGHs lipolytic function from its growth-promoting and insulin-desensitizing effects, producing a compound studied almost exclusively in the context of fat metabolism rather than general growth hormone replacement
Composition AOD 9604 Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions For qualified research professionals and institutional laboratories
.webp)
For the maintenance treatment of pernicious anemia, the usual dose is 100mcg SC/IM, given once every month
Developed by Metabolic Pharmaceuticals in Australia, AOD-9604 was engineered to retain the fat-reducing properties of intact growth hormone while eliminating the undesirable effects on glucose metabolism, insulin sensitivity, and tissue growth
(2) NNMT catalyzes the N-methylation of nicotinamide using SAM as a methyl donor, consuming both substrates in the process
